Cladis Investment Advisory, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Cladis Investment Advisory, LLC
- $144 Billion
- Q3 2024
A detailed history of Cladis Investment Advisory, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Cladis Investment Advisory, LLC holds 10,000 shares of CPRX stock, worth $208,700. This represents 0.14% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$208,700
Previous $155 Million
28.34%
% of portfolio
0.14%
Previous 0.11%
Shares
2 transactions
Others Institutions Holding CPRX
# of Institutions
326Shares Held
94MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$390 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$168 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$130 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$119 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$63 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.15B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...